Search

Displaying results 6901 - 6910 of 9886 in total
  1. Drug

    αAβ–Gas6

    go.drugbank.com/drugs/DB17069
    Experimental

    It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is a ligand … αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD).

  2. Drug

    Tabelecleucel

    go.drugbank.com/drugs/DB17072
    ApprovedInvestigational

    When given to a patient with EBV-associated post-transplant lymphoproliferative disorder (PTLD) following solid organ transplantation (SOT) or hematopoietic cell transplant, T-cells attack the patient's

  3. Drug

    Lifileucel

    go.drugbank.com/drugs/DB17107
    ApprovedInvestigational

    Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and activation[A263341

  4. Drug

    ZB131

    go.drugbank.com/drugs/DB17164
    Investigational

    ZB131 is a monoclonal antibody with a high affinity and specificity for cancer-specific plectin (CSP), a cell surface protein identified in a wide range of cancers that correlates with poor prognosis and

  5. Drug

    BCL-005

    go.drugbank.com/drugs/DB17242
    Experimental

    BCL-005 is a product formed by fused (hybrid) melanoma-dendritic cells.

  6. Drug

    GI-101

    go.drugbank.com/drugs/DB17243
    Investigational

    GI-101 is a bi-specific fragment crystallizable region (Fc) fusion protein containing a cluster of differentiation 80 ectodomain as an N-terminal moiety and interleukin-2 variant as a C-terminal moiety

  7. Drug

    ISB 1342

    go.drugbank.com/drugs/DB17251
    Investigational

    ISB 1342 is a bispecific antibody simultaneously targeting CD38 and CD3.

  8. Drug

    Tarlatamab

    go.drugbank.com/drugs/DB17256
    ApprovedInvestigational

    Tarlatamab is a first-in-class T-cell engager used to treat extensive-stage small cell lung cancer. … [L50748] It is a bispecific monoclonal antibody that targets CD3 expressed on the surface of T-cells and delta-like ligand 3 (DLL3), an inhibitory ligand that suppresses Notch signaling and is highly expressed

  9. Drug

    Etentamig

    go.drugbank.com/drugs/DB17268
    Investigational

    TNB-383B is a CD3 and B-cell maturation antigen T-cell engaging bispecific antibody.

  10. Drug

    Cirtuvivint

    go.drugbank.com/drugs/DB17269
    Investigational

    Cirtuvivint is a first-in-class CDC-like kinase (CLK) inhibitor.